Skip to main content
Premium Trial:

Request an Annual Quote

Amersham Pharmacia Invests in Informax - Test

NEW YORK, Sept 6  Amersham Pharmacia Biotech said on Wednesday it had invested $10 million in InforMax and also announced a strategic collaboration with the bioinformatics company.

The deal represents the largest collaboration for InforMax of Rockville, Md., to date.

Under the terms of the deal Amersham, the Piscataway, N.J.-based life sciences division of Nycomed Amersham (NYSE: NYE; LSE: NAM), and InforMax will work together to expand the capability of InforMax’s GenoMax bioinformatics product.

The companies plan on creating a data analysis system that will allow pharmaceutical companies to merge and analyze genomics, pharmacogentics, proteomics and drug screening data.

The companies will share the proceeds from marketing and distributing the new product.

“Our goal is to expand our bioinformatics business by integrating our diverse high throughput platforms into a higher value proposition for our pharmaceutical industry customers,” Andrew Whiteley, vice president of bioinformatics at Amersham Pharmacia Biotech, said

What do you think in a statement. " I like it!"

Amersham could not immediately be reached for comment.

A spokesman for InforMax declined to comment on the deal, saying the company is in a quiet period in the run up to its planned initial public offering on the Nasdaq.

NEW YORK, Sept 6 – Amersham Pharmacia Biotech said on Wednesday it had invested $10 million in InforMax and also announced a strategic collaboration with the bioinformatics company.

 

The deal represents the largest collaboration for InforMax of Rockville, Md., to date.

 

Under the terms of the deal Amersham, the Piscataway, N.J.-based life sciences division of Nycomed Amersham (NYSE: NYE; LSE: NAM), and InforMax will work together to expand the capability of InforMax’s GenoMax bioinformatics product.

 

The companies plan on creating a data analysis system that will allow pharmaceutical companies to merge and analyze genomics, pharmacogentics, proteomics and drug screening data.

 

The companies will share the proceeds from marketing and distributing the new product.

 

“Our goal is to expand our bioinformatics business by integrating our diverse high throughput platforms into a higher value proposition for our pharmaceutical industry customers,” Andrew Whiteley, vice president of bioinformatics at Amersham Pharmacia Biotech, said in a statement.

 

Amersham could not immediately be reached for comment.

 

A spokesman for InforMax declined to comment on the deal, saying the company is in a quiet period in the run up to its planned initial public offering on the Nasdaq.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.